Fennec Pharmaceuticals Inc.
FENC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001211583
In the last 90 days, Fennec Pharmaceuticals Inc. insiders filed 0 open-market purchases and 6 sales; 105 institutions reported holding it in 13F filings for Q2 2026, worth $175.1M in total; no superinvestor holds it.
Holders of 5% or more of FENC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Fennec Pharmaceuticals Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Rosalind Advisors, Inc. | 13G/A | 8.80%3.04M shares | −1.00 ppfrom 9.80% | Nov 13, 20253 filings | May 14, 2026 | SEC |
| Sonic Fund II, L.P. | 13G/A | 8.20%2.80M shares | – | Feb 17, 20261 filing | Feb 17, 2026 | SEC |
| Southpoint Capital Advisors LP | 13G/A | 8.00%2.74M shares | – | Jan 14, 20261 filing | Jan 14, 2026 | SEC |
| Solas Capital Management, LLC | 13G/A | 7.20%2.48M shares | −1.00 ppfrom 8.20% | Nov 14, 20243 filings | May 15, 2026 | SEC |
| Hirschman Orin | 13G | 5.70%1.98M shares | New | Apr 28, 20261 filing | Apr 28, 2026 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
10 Schedule 13D and 13G filings on Fennec Pharmaceuticals Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| May 15, 202610:58 AM ET | Solas Capital Management, LLCand 1 other | 13G/A | 7.20%2.48M shares | −1.00 ppfrom 8.20% | Mar 31, 2026 | SEC |
| May 14, 20262:50 PM ET | Rosalind Advisors, Inc.and 3 others | 13G/A | 8.80%3.04M shares | −1.00 ppfrom 9.80% | Mar 31, 2026 | SEC |
| Apr 28, 20264:15 PM ET | Hirschman Orinand 1 other | 13G | 5.70%1.98M shares | New | Mar 31, 2026 | SEC |
| Feb 17, 202610:39 AM ET | Sonic Fund II, L.P.and 2 others | 13G/A | 8.20%2.80M shares | – | Dec 31, 2025 | SEC |
| Feb 11, 20261:58 PM ET | Rosalind Advisors, Inc.and 3 others | 13G/A | 9.80%2.75M shares | +2.30 ppfrom 7.50% | Dec 31, 2025 | SEC |
| Jan 14, 20265:00 PM ET | Southpoint Capital Advisors LPand 5 others | 13G/A | 8.00%2.74M shares | – | Dec 31, 2025 | SEC |
| Nov 13, 20254:08 PM ET | Rosalind Advisors, Inc.and 3 others | 13G | 7.50%2.08M shares | New | Sep 30, 2025 | SEC |
| Feb 14, 20251:00 PM ET | Solas Capital Management, LLCand 1 other | 13G/A | 8.20%2.25M shares | +1.20 ppfrom 7.00% | Dec 31, 2024 | SEC |
| Feb 14, 202512:06 PM ET | DG Capital Management, LLCand 2 others | 13G/A | 4.10%1.11M shares | –Below 5% | Dec 31, 2024 | SEC |
| Nov 14, 20241:58 PM ET | Solas Capital Management, LLCand 1 other | 13G/A | 7.00%1.92M shares | – | Sep 30, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Fennec Pharmaceuticals Inc. shares.
No Form 144 notices for Fennec Pharmaceuticals Inc. are on file.